Since December 2019, SARS-CoV-2 is ravaging the globe, currently accounting for over
660 million infected people and more than 6.6 million deaths. As convalescent plasma had …

Antibody-based therapy for infectious diseases predates modern antibiotics and, in the
absence of other therapeutic options, was deployed early in the SARS-CoV-2 pandemic …

Introduction When the COVID-19 pandemic struck no specific therapies were available and
many turned to COVID-19 convalescent plasma (CCP), a form of antibody therapy. The …

Importance Patients who are immunocompromised have increased risk for morbidity and
mortality associated with coronavirus disease 2019 (COVID-19) because they less …

COVID-19 convalescent plasma (CCP) is an investigational treatment for SARS-CoV-2
infection. Several lines of evidence, ranging from expanded access programmes (EAP) to …

ABSTRACT COVID-19 convalescent plasma (CCP) was an early and widely adopted
putative therapy for severe COVID-19. Results from randomized control trials and …

The potential for antibody-based COVID-19 treatments received significant attention early
during the pandemic. As COVID-19 vaccines have been developed, approved and …

Amidst the therapeutic void at the onset of the COVID-19 pandemic, a critical mass of
scientific and clinical interest coalesced around COVID-19 convalescent plasma (CCP). To …

As the coronavirus disease (COVID-19) pandemic led to a global health crisis, there were
limited treatment options and no prophylactic therapies for those exposed to severe acute …

Convalescent plasma (CP) recurs as a frontline treatment in epidemics because it is
available as soon as there are survivors. The COVID-19 pandemic represented the first …